PureTech HealthLSE:PRTC +0.50%63 Cyclically Adjusted PS Ratio is 60.00 as of Jul. 11, 2026, which is 22% below its 10-year median of 76.85. GuruFocus rates LSE:PRTC with a GF Score™ of 63/100 and a GF Value™ of £5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 538 Biotechnology companies, PureTech Health ranks worse than 91.82% on this metric.
The historical rank and industry rank for PureTech Health's Cyclically Adjusted PS Ratio or its related term are showing as below:
LSE:PRTC'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 49.2 Med: 76.85 Max: 135
Current: 58.71
During the past 13 years, PureTech Health's highest Cyclically Adjusted PS Ratio was 135.00. The lowest was 49.20. And the median was 76.85.
LSE:PRTC's Cyclically Adjusted PS Ratio is ranked worse than 91.82% of 538
companies
in the Biotechnology industry
Industry Median: 5.85
vs LSE:PRTC: 58.71
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
PureTech Health's adjusted revenue per share data of for the fiscal year that ended in Dec25 was £0.014. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is £0.02 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
PureTech Health (LSE:PRTC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
PureTech Health Cyclically Adjusted PS Ratio Related Terms
PureTech Health Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for PureTech Health's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health Cyclically Adjusted PS Ratio Chart
LSE:PRTC vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, PureTech Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where PureTech Health's Cyclically Adjusted PS Ratio falls into.
PureTech Health Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
PureTech Health's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 60.00 mean?
PureTech Health (LSE:PRTC) has a Cyclically Adjusted PS Ratio of 60.00 as of Jul. 11, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on PureTech Health and its competitors. This is 22% below median its historical median of 76.85. Over the past decade, PureTech Health's Cyclically Adjusted PS Ratio has ranged from 49.20 to 135.00. According to the industry distribution chart, PureTech Health ranks #494 out of 538 companies in the Biotechnology industry, placing it in the top 91.8%.
Is PureTech Health's Cyclically Adjusted PS Ratio too high?
PureTech Health's current Cyclically Adjusted PS Ratio of 60.00 is 22% below median its 10-year median of 76.85. Over the past 10 years, this metric has ranged from a low of 49.20 to a high of 135.00. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.85. PureTech Health's value of 60.00 is 925.6% above this industry median. Based on the distribution chart, PureTech Health ranks #494 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PureTech Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #494 out of 538 companies for Cyclically Adjusted PS Ratio. This places PureTech Health in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.85. PureTech Health's value of 60.00 is 925.6% above this benchmark. Historically, PureTech Health's own Cyclically Adjusted PS Ratio has ranged from 49.20 to 135.00 over the past decade. While the company's 10-year median is 76.85 vs. the industry median of 5.85, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.85, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Cyclically Adjusted PS Ratio of 60.00 is 925.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Cyclically Adjusted PS Ratio is 60.00, which is 22% below median its own 10-year median of 76.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (LSE:PRTC) is currently considered Possible Value Trap. The stock's GF Value™ is £5.31, compared to a current price of £1.20 — trading 77.4% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 60.00, which is 22% below median its 10-year median of 76.85 and 925.6% above the Biotechnology industry median of 5.85. PureTech Health's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For PureTech Health (LSE:PRTC), the current Cyclically Adjusted PS Ratio is 60.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (LSE:PRTC) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.20 is trading 77.4% below its estimated GF Value™ of £5.31.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for LSE:PRTC:
Cyclically Adjusted PS Ratio: 60.00 (22% below median its 10-year median of 76.85)
GF Value™: £5.31 vs. price of £1.20 (77.4% below fair value)
Industry Position: 925.6% above the Biotechnology median (#494 of 538)
No single metric tells the full story. See the LSE:PRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
63GF Score
Get the complete analysis for LSE:PRTC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:PRTC has been successfully added to your 
